Multipotent Adult Progenitor Cells (MAPC) contribute to hepatocarcinoma neovasculature

Barajas, Miguel; Franchi, Federico; Clavel, Carlos; Aranguren, Xabier L.; Kramer, M. Gabriela; Abizanda, Gloria; Merino, Juana; Moreno, Cristina; Gárate, Leire; Guitart, Anunciata; Narvaiza, Iñigo; Gutiérrez-Pérez, María; Riezu-Boj, José Ignacio; Berasain, Carmen; Prieto, Jesús; Prósper, Felipe

doi:10.1016/j.bbrc.2007.09.106

Cited by 12 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[26][27][28] Recently, several studies suggested that both HBV-related ICC and hepatocellular carcinoma (HCC) held common disease processes for carcinogenesis, and may originate from hepatic progenitor cells. [29][30][31][32] As evidence, proportion of AFP elevation was far higher in HBV-related ICC when compared to ICC with HBsAg negative. 32,33 However, our study showed that AFP was in the normal level for most ECC cases, regardless of the HBV infection state.…”

Section: Discussionmentioning

confidence: 82%

Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism

Zhou

et al. 2013

Int. J. Cancer

View full text Add to dashboard Cite

Little is known about the role of association between ABO blood group and development of extrahepatic cholangiocarcinoma (ECC) through effects on hepatitis B viral (HBV) infection. Our aim was to address this question using a matched case-control study in Southern China.We prospectively analyzed 239 ECC patients, and 478 age-and sex-matched controls in Sun Yat-sen Memorial Hospital of Sun Yat-sen University from 1999 to 2011. Information on ABO blood group, HBV infection and other clinicopathologic factors was collected. Adjusted odds ratios (AORs) and the corresponding 95% confidence intervals (CIs) were computed from unconditional logistic regression models, adjusted for major confounding factors. The estimated AORs were as follows: A blood group, 1.784; HBsAg1/HbcAb1, 1.848 and HBsAg2/HbcAb1, 1.501. The A blood type had a significant effect on modifying the risk of ECC among subjects with HBsAg1/HbcAb1 (AOR 3.795, 95% CI 1.427-10.090). ECC patients with A blood group were more common in younger subjects, and a lower proportion of serum CA-125 and CA19-9 elevation in patients with blood type A was found. Our study suggests an association between A blood type, HBV infection and ECC risk, and a synergism between A blood type and HBV infection in the development of ECC.Cholangiocarcinoma (CC) is a malignant neoplasm of the biliary-duct system accounting for 10-25% of the primary hepatic malignancies worldwide.1 Recent study showed that the incidence and mortality rates of CC have been increasing worldwide including China.2-6 Although several risk factors for CC, including parasitic infection, primary sclerosing cholangitis, anatomical abnormalities and hepatolithiasis, have been established, some potential factors such as hepatitis virus infection and host genetic polymorphisms remain debating. 7 Meanwhile, data showed that potential risk factors might have different effect on CC, depending on the anatomical site. 8 The role of HBV in ECC is not entirely clear, and the related studies have different conclusions. 7 The prevalence rate of infection with hepatitis B virus (HBV) varies widely among different parts of the world; it can range from near zero to more than 10%.9 China is a typical highly endemic area of HBV infection. The effect of HBV infection on the incidence, age or sex distribution and clinicopathologic parameters of intrahepatic cholangiocarcinoma (ICC) has been documented by many studies, but the role of HBV in the development of extrahepatic cholangiocarcinoma (ECC) in viral hepatitis B endemic areas was less reported and remains to be addressed.Furthermore, several genome-wide studies demonstrated that ABO blood group antigens may alter the systemic inflammatory response. And, blood antigens are also known

show abstract

Section: Discussionmentioning

confidence: 82%

Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism

Zhou

et al. 2013

Int. J. Cancer

View full text Add to dashboard Cite

show abstract

“…The degree of reactivation of hepatic progenitor cells has been associated with the degree of inflammatory activity in viral hepatitis and cirrhosis (Roskams et al, 2003;Roskams, 2006). Recently, cells with stemness properties have been identified in human HCC, further supporting the speculation that hepatic progenitor cells are involved in the carcinogenesis of HCC as well as ICC (Barajas et al, 2007;Ma et al, 2007;Yamashita et al, 2007;Zen et al, 2007;Qiao et al, 2008;Yang et al, 2008;Zhang et al, 2008).…”

Section: Discussionmentioning

confidence: 98%

Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma

et al. 2009

View full text Add to dashboard Cite

Bile duct cells and hepatocytes differentiate from the same hepatic progenitor cells. To investigate the possible association of viral hepatitis B and C with intrahepatic cholangiocarcinoma (ICC), we conducted a retrospective case -control study using univariate and multivariate logistic analyses to identify risk factors for ICC. Besides hepatic lithiasis (25.6%; Po0.001), seropositivity for hepatitis B surface antigen (37.5% of all ICC patients; odds ratio (OR) ¼ 4.985, Po0.001) and seropositivity for hepatitis C antibodies (13.1%; OR ¼ 2.709; P ¼ 0.021) are the primary independent risk factors for ICC. Cirrhosis exerted synergic effects on the development of ICC. We compared the age distributions of viral-hepatitis associated ICC to that of viral hepatitis-associated hepatocellular carcinoma (HCC). The mean age of ICC patients with viral hepatitis B (56.4 ± 11.1 years) were 9 years younger than that of ICC patients with viral hepatitis C (65.6 ± 9.17 years), similar to that observed in HCC. The incidence ratio of HCC : ICC : CHC (combined hepatocellular cholangiocarcinoma) in our population was 233 : 17 : 1 consistent with the theoretic ratio of hepatocyte number to cholangiocyte number in the liver. Our findings indicated that both viral hepatitis-associated ICC and HCC shared common disease process for carcinogenesis and, possibly, both arose from the hepatic progenitor cells.

show abstract

“…Far from being a hindrance for research purposes, one can interpret this heterogeneity as a biological measure of non-clonal derivation of subpopulations of MSCs in standard protocols. 18,47 In this regard, MSCs plated on fibronectin-coated plates and incubated in embryonic stem cell culture medium express embryonic stem cell markers such as SSEA-1, Oct-4 and Nanog and present pluripotent-like properties, 15,44,48,49 and because of their unique properties they were named as 'multipotent adult progenitor cells' and 'marrow isolated adult multilineage inducible stem cells'. It is noteworthy that multipotent adult progenitor cells present an expression profile that significantly differs from that of MSCs cultured on plastic regarding markers such as CD44 and H-2K (MHC I, RT1a).…”

Section: Mscs: Mesenchymal Stem (Or Stromal) Cells? How Broad Is Theimentioning

confidence: 99%

“…It is noteworthy that multipotent adult progenitor cells present an expression profile that significantly differs from that of MSCs cultured on plastic regarding markers such as CD44 and H-2K (MHC I, RT1a). 44,48,50,51 Changes in the expression levels of these two factors have potential implications in MSC adhesiveness or immunological properties and might be therefore relevant for cell therapy purposes.…”

Section: Mscs: Mesenchymal Stem (Or Stromal) Cells? How Broad Is Theimentioning

confidence: 99%

Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

Mesenchymal stem (stromal) cells (MSCs) are a source of circulating progenitors that are able to generate cells of all mesenchymal lineages and to cover cellular demands of injured tissues. The extent of their transdifferentiation plasticity remains controversial. Cells with MSC properties have been obtained from diverse tissues after purification and expansion in vitro. These cellular populations are heterogeneous and under certain conditions show pluripotent-like properties. MSCs present immunosuppressive and anti-inflammatory features and high migratory capacity toward inflamed or remodeling tissues. In this study we review available data regarding factors and signaling axes involved in the chemoattraction and engraftment of MSCs to an injured tissue or to a tissue undergoing active remodeling. Moreover, experimental evidence in support of uses of MSCs as vehicles of therapeutic genes is discussed. Because of its regenerative capacity and its particular immune properties, the liver is a good model to analyze the potential of MSCbased therapies. Finally, the potential application of MSCs and genetically modified MSCs in liver fibrosis and hepatocellular carcinoma (HCC) is proposed in view of available evidence.

show abstract

Multipotent Adult Progenitor Cells (MAPC) contribute to hepatocarcinoma neovasculature

Cited by 12 publications

References 25 publications

Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism

Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism

Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma

Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma

Contact Info

Product

Resources

About